Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.

Trial Details

NCT ID
NCT07453095
Phase
PHASE2
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
Locations (sample)
  • Alessandria, Italy|44.90924,8.61007
  • Bologna, Italy|44.49381,11.33875
  • Brescia, Italy|45.53558,10.21472
  • Florence, Italy|43.77925,11.24626
  • Genova, Italy|45.21604,11.87211

Key Eligibility Criteria

  • Able to provide written informed consent forms approved by the National Ethics Committee (NEC) prior to the initiation of any screening or study-sp…
  • Histologically confirmed MCL after CAR T-cells failure (CD20+ by flow cytometry or immunohistochemistry). Note: Availability of archival material i…
  • Patients who received CAR T-cells therapy for R/R MCL at least 30 days prior to signing the informed consent form and who meet one of the following…
  • Stable disease (SD) or progressive disease (PD) up to D+90; after CAR T-cells infusion (from D+30 to D+90);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →